Seres grabs $20M on PhIII microbiome launch; Gilead submits NDA; Alkermes begins Phase IIIb study
→ Seres $MCRB is taking another step forward in its comeback effort on a microbiome drug that rattled everyone in the field when it failed a mid-stage study. The biotech says that it has learned from its setback and has now started a study for patients with multiple recurrent C. difficile infection that it’s hoping will serve as the pivotal Phase III for SER-109. That move — the most advanced microbiome study in the gut research world — was worth a $20 million milestone payment from its partners at Nestlé Health Science.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
